U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H20ClN3.C6H8O7
Molecular Weight 529.969
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JNJ-18038683

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.ClC1=CC=C(C=C1)C2=NN(CC3=CC=CC=C3)C4=C2CCNCC4

InChI

InChIKey=DIQZMBPDLFAJLK-UHFFFAOYSA-N
InChI=1S/C20H20ClN3.C6H8O7/c21-17-8-6-16(7-9-17)20-18-10-12-22-13-11-19(18)24(23-20)14-15-4-2-1-3-5-15;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-9,22H,10-14H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI
Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C20H20ClN3
Molecular Weight 337.846
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

JNJ-18038683 is a 5-hydroxytryptamine type 7 receptor antagonist with potential antidepressant efficacy. It is under development for the treatment of the bipolar disorder.

Originator

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder.
2012 Aug
Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity.
2014

Sample Use Guides

In Vivo Use Guide
10-20 mg/day for 8 weeks.
Route of Administration: Oral
In Vitro Use Guide
JNJ-18038683 displaced, with high affinity, specific [3H]5-carboxamidotryptamine binding sites from rat and human 5-hydroxytryptamine type 7 (5-HT7) receptor expressed in HEK293 cells (pKi=8.19+/-0.02 and 8.20+/-0.01, respectively). Similar values are obtained on the native 5-HT7 in membranes from rat thalamus (pKi=8.50+/-0.20). Antagonist potency of JNJ-18038683 is determined by the measurement of adenylate cyclase activity in HEK293 cells expressing the human or rat 5-HT7 receptor. 5-hydroxytryptamine stimulates adenylyl cyclase activity in rat and human 5-HT7/HEK293 cells with a pEC50 of 8.09 and 8.12, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:03:09 UTC 2023
Edited
by admin
on Fri Dec 15 16:03:09 UTC 2023
Record UNII
9UKQ1NQ8YX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
JNJ-18038683
Common Name English
PYRAZOLO(3,4-D)AZEPINE, 3-(4-CHLOROPHENYL)-1,4,5,6,7,8-HEXAHYDRO-1-(PHENYLMETHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) (SALT)
Common Name English
Code System Code Type Description
CAS
851376-05-1
Created by admin on Fri Dec 15 16:03:09 UTC 2023 , Edited by admin on Fri Dec 15 16:03:09 UTC 2023
PRIMARY
FDA UNII
9UKQ1NQ8YX
Created by admin on Fri Dec 15 16:03:09 UTC 2023 , Edited by admin on Fri Dec 15 16:03:09 UTC 2023
PRIMARY
PUBCHEM
11249539
Created by admin on Fri Dec 15 16:03:09 UTC 2023 , Edited by admin on Fri Dec 15 16:03:09 UTC 2023
PRIMARY
Related Record Type Details
Structure of ANHYDROUS CITRIC ACID
PARENT -> SALT/SOLVATE
Structure of JNJ-18038683 FREE BASE
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966